🇺🇸 metformin + glimepiride in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Myalgia — 2 reports (18.18%)
  2. Alopecia — 1 report (9.09%)
  3. Arteriosclerosis — 1 report (9.09%)
  4. Arthralgia — 1 report (9.09%)
  5. Blister — 1 report (9.09%)
  6. Blood Glucose Increased — 1 report (9.09%)
  7. Blood Pressure Systolic Increased — 1 report (9.09%)
  8. Cerebral Haemorrhage — 1 report (9.09%)
  9. Dizziness — 1 report (9.09%)
  10. Drug Ineffective — 1 report (9.09%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is metformin + glimepiride approved in United States?

metformin + glimepiride does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for metformin + glimepiride in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.